Funding
P.K., Atrial Fibrillation, Stroke
IMI, HEART, ATRIAL FIBRILLATION, STROKE
EAST-AFNET4 (Early Treatment of Atrial Fibrillation for Stroke Prevention Trial) was funded in part by BMBF (German Ministry of Education and Research, Berlin, Germany, Grant 01 GI 0204), DZHK (German Center for Cardiovascular Research, Berlin, Germany, 81Z0710102), AFNET (Atrial Fibrillation Network), European Heart Rhythm Association, St Jude Medical/Abbott, Sanofi, and the German Heart Foundation.Further support of this analysis came from AFNET, the European Union Horizon 2020 [grant agreement No. 633196 (CATCH ME) to P.K. and L.F.; AFFECT-EU grant agreement number 847770 to R.B.S., P.K., L.F.; MAESTRIA (grant agreement number 965286) to L.F. and P.E., grant agreement EU IMI 116074 (BigData@Heart) to P.K.], the British Heart Foundation (FS/13/43/30324; PG/17/30/32961; PG/20/22/35093 to P.K.; AA/18/2/34218 to P.K. and L.F.), the Leducq Foundation to P.E. and P.K., the National Institutes of Health (1RO1HL092577, 1R01HL157635, 5R01HL139731) to P.E., and the American Heart Association (18SFRN34110082) to P.E. J.P.P. has received support from the Sarnoff Cardiovascular Research Foundation (Scholar Award) and from the National Institutes of Health (K08HL159346). T.Z. is funded by the German Research Foundation, the EU Horizon 2020 program and the EU ERANet and ERAPreMed programs.The use of the UK Biobank resource was approved by the Mass General Brigham IRB and conducted under UK Biobank application #7089.